Jun 15, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
NuPathe To Present Additional Migraine Patch Data From Three Trials At AHS
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2567468" data-attributes="member: 124445"><p>NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders, today announced that additional data from a 12-month open-label trial of its transdermal migraine patch (also referred to as Zelrix and NP101) and two other Zelrix trials will be presented at the 53rd Annual Scientific Meeting of the American Headache Society (AHS) this week in Washington, DC... <a href="http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/_ns4ID-bEkw" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/_ns4ID-bEkw/227351.php" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2567468, member: 124445"] NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders, today announced that additional data from a 12-month open-label trial of its transdermal migraine patch (also referred to as Zelrix and NP101) and two other Zelrix trials will be presented at the 53rd Annual Scientific Meeting of the American Headache Society (AHS) this week in Washington, DC... [URL="http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/0/da"][IMG]http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/1/da"][IMG]http://feedads.g.doubleclick.net/~a/C2wcOos1kx3e3IpFN8-KbEr0xoA/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/_ns4ID-bEkw[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/_ns4ID-bEkw/227351.php]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top